Renal Response Criteria for Clinical Trials in Amyloid Light Chain Amyloidosis

[1]  M. Gertz,et al.  Peripheral Nervous, Hepatic, and Gastrointestinal Endpoints for AL Amyloidosis Clinical Trials: Report from the Amyloidosis Forum Multi-organ System Working Group , 2023, Advances in therapy.

[2]  P. Schmitt,et al.  Health-Related Quality of Life Instruments for Clinical Trials in AL Amyloidosis: Report from the Amyloidosis Forum HRQOL Working Group , 2023, Patient related outcome measures.

[3]  S. Kennel,et al.  Clinical Confirmation of Pan-Amyloid Reactivity of Radioiodinated Peptide 124I-p5+14 (AT-01) in Patients with Diverse Types of Systemic Amyloidosis Demonstrated by PET/CT Imaging , 2023, Pharmaceuticals.

[4]  C. Rapezzi,et al.  Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group , 2022, Circulation. Heart failure.

[5]  G. Doros,et al.  Correlation Between 24-Hour Urine Protein and Random Urine Protein-Creatinine Ratio in Amyloid Light-Chain Amyloidosis , 2022, Kidney medicine.

[6]  A. Foli,et al.  Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients , 2022, Clinical chemistry and laboratory medicine.

[7]  N. Powe,et al.  New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. , 2021, The New England journal of medicine.

[8]  M. Beksac,et al.  Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. , 2021, The New England journal of medicine.

[9]  Lisa E. Vaughan,et al.  Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort , 2021, American journal of hematology.

[10]  S. Vincent Rajkumar,et al.  Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients , 2020, Blood Cancer Journal.

[11]  R. Falk,et al.  The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis , 2020, Orphanet Journal of Rare Diseases.

[12]  M. Dimopoulos,et al.  Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Neetika Garg,et al.  Performance of Creatinine Clearance and Estimated GFR in Assessing Kidney Function in Living Donor Candidates , 2020, Transplantation.

[14]  D. Dingli,et al.  A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry–Verified Typing , 2019, Mayo Clinic proceedings.

[15]  M. Dimopoulos,et al.  Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. , 2018, Blood.

[16]  M. Dimopoulos,et al.  Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy , 2017, American journal of hematology.

[17]  D. Dingli,et al.  Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition , 2017, Annals of medicine.

[18]  A. Foli,et al.  Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis , 2017, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[19]  M. Dimopoulos,et al.  Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. , 2016, Blood.

[20]  M. Hayashi,et al.  Renal function evaluation in patients with cancer who were scheduled to receive carboplatin or S-1 , 2015, Clinical and Experimental Nephrology.

[21]  A. Foli,et al.  A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. , 2014, Blood.

[22]  Ahmet Dogan,et al.  Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[23]  D. Dingli,et al.  A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision? , 2013, Haematologica.

[24]  S. Cha,et al.  Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[25]  R. Falk,et al.  Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis , 2012, Leukemia.

[26]  S. Chadban,et al.  Day-to-day variability in spot urine protein-creatinine ratio measurements. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  P. L. Bergsagel,et al.  Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. , 2012, Blood.

[28]  D. Dingli,et al.  Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Döhner,et al.  Prognostic significance of serum cystatin C in multiple myeloma , 2012, International Journal of Hematology.

[30]  A. Dispenzieri,et al.  Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[31]  T. Larson,et al.  Relative performance of the MDRD and CKD-EPI equations for estimating glomerular filtration rate among patients with varied clinical presentations. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[32]  D. Dingli,et al.  Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006 , 2011, Bone Marrow Transplantation.

[33]  F. Dekker,et al.  Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[34]  L. Stevens,et al.  Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[36]  G. Beck,et al.  Factors other than glomerular filtration rate affect serum cystatin C levels. , 2009, Kidney international.

[37]  M. Dimopoulos,et al.  Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration , 2009, Haematologica.

[38]  D. Dingli,et al.  Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[39]  F. Jardin,et al.  High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. , 2007, The New England journal of medicine.

[40]  S. Cha,et al.  Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[41]  R. Falk,et al.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.

[42]  G. Merlini,et al.  Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. , 2004, Blood.

[43]  R. Falk,et al.  High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study , 2004, Annals of Internal Medicine.

[44]  Giampaolo Merlini,et al.  Molecular mechanisms of amyloidosis. , 2003, The New England journal of medicine.

[45]  J. D. Vos,et al.  Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays , 2002, Oncogene.

[46]  R. Orlando,et al.  Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis. , 2002, Clinical chemistry.

[47]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[48]  T. Therneau,et al.  A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. , 1997, The New England journal of medicine.

[49]  E. Shpall,et al.  Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. , 1996, Kidney international.

[50]  M. Koopman,et al.  Discrepancy between circadian rhythms of inulin and creatinine clearance. , 1992, The Journal of laboratory and clinical medicine.

[51]  J P Kriss,et al.  Limitations of creatinine as a filtration marker in glomerulopathic patients. , 1985, Kidney international.

[52]  J. Bauer,et al.  Clinical appraisal of creatinine clearance as a measurement of glomerular filtration rate. , 1982, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[53]  J. Lieske,et al.  Challenges in Measuring Glomerular Filtration Rate: A Clinical Laboratory Perspective. , 2018, Advances in chronic kidney disease.

[54]  D. Fliser,et al.  Serum cystatin C concentration as a marker of renal dysfunction in the elderly. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.